{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:39Z","timestamp":1794047559956,"version":"4.8.0"},"reference-count":0,"publisher":"Ferrata Storti Foundation (Haematologica)","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Triplets incorporating proteasome inhibitors, immunomodulatory drugs, and dexamethasone are active regimens for patients with relapsed\/refractory multiple myeloma (RRMM). All-oral regimens may offer greater real-world feasibility and convenience than other options. This phase I\/II dose-escalation and expansion study evaluated the oral proteasome inhibitor ixazomib at a dose of 3 or 4 mg on a twice-weekly schedule (days 1, 4, 8, and 11) in 21-day cycles, plus pomalidomide at a dose of 2, 3, or 4 mg (days 1\u201314) and dexamethasone 12 or 8 mg (days of\/after ixazomib), in 50 patients with RRMM. Patients had received a median of 2 prior lines, with 98.0% and 88.0% having received prior lenalidomide and bortezomib, respectively. The highest dose level investigated (ixazomib 4 mg, pomalidomide 4 mg) was the recommended phase II dose (RP2D). Patients received a median of 11 cycles. Common toxicities were neutropenia (76.0%; grade 3\/4 22.0%\/4.0%), thrombocytopenia (70.0%; 8.0%\/8.0%), leukopenia (68.0%; 22.0%\/0%), fatigue (52.0%; 4.0%\/0%), and anemia (46.0%; 2.0%\/0%). During dose escalation, two dose-limiting toxicities (grade 3 upper respiratory tract infection; grade 3 neutropenia) were reported. The overall response rate was 60.0% (24.0% \u2265very good partial response [VGPR]) in all 50 patients and 65.8% (28.9% \u2265VGPR) in the 38 patients who received the RP2D; the median duration of response was 18.0 and 19.3 months, median progression-free survival was 13.9 and 17.8 months, and 3-year overall survival rates were 85.2% and 80.3%, respectively. Twice-weekly ixazomib plus pomalidomide-dexamethasone is a well-tolerated, efficacious all-oral regimen with real-world utility in RRMM.<\/jats:p>","DOI":"10.3324\/haematol.2026.300897","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:58:10Z","timestamp":1779955090000},"source":"Crossref","is-referenced-by-count":0,"title":["A phase I\/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma"],"prefix":"10.3324","author":[{"given":"Omar","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton C.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Reagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique A.","family":"Hartley-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison P.","family":"Chuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Distaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie Van","family":"Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Dahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Goldbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keemia","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Poda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2026,5,28]]},"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/14216\/80381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/14216\/80381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:14:17Z","timestamp":1794046457000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/14216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":0,"URL":"https:\/\/doi.org\/10.3324\/haematol.2026.300897","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}